Literature DB >> 28837208

Platelet count recovery and seroreversion in immune HIT despite continuation of heparin: further observations and literature review.

Andrew W Shih1, Jo-Ann I Sheppard, Theodore E Warkentin.   

Abstract

One of the standard distinctions between type 1 (non-immune) and type 2 (immune-mediated) heparin-induced thrombocytopenia (HIT) is the transience of thrombocytopenia: type 1 HIT is viewed as early-onset and transient thrombocytopenia, with platelet count recovery despite continuing heparin administration. In contrast, type 2 HIT is viewed as later-onset (i. e., 5 days or later) thrombocytopenia in which it is generally believed that platelet count recovery will not occur unless heparin is discontinued. However, older reports of type 2 HIT sometimes did include the unexpected observation that platelet counts could recover despite continued heparin administration, although without information provided regarding changes in HIT antibody levels in association with platelet count recovery. In recent years, some reports of type 2 HIT have confirmed the observation that platelet count recovery can occur despite continuing heparin administration, with serological evidence of waning levels of HIT antibodies ("seroreversion"). We now report two additional patient cases of type 2 HIT with platelet count recovery despite ongoing therapeutic-dose (1 case) or prophylactic-dose (1 case) heparin administration, in which we demonstrate concomitant waning of HIT antibody levels. We further review the literature describing this phenomenon of HIT antibody seroreversion and platelet count recovery despite continuing heparin administration. Our observations add to the concept that HIT represents a remarkably transient immune response, including sometimes even when heparin is continued.

Entities:  

Keywords:  Deep vein thrombosis; heparins; pulmonary embolism; thrombosis

Mesh:

Substances:

Year:  2017        PMID: 28837208     DOI: 10.1160/TH17-03-0212

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  2 in total

1.  Timeline of heparin-induced thrombocytopenia seroconversion in serial plasma samples tested using an automated latex immunoturbidimetric assay.

Authors:  Theodore E Warkentin; Jo-Ann I Sheppard; James W Smith; Donald M Arnold; Ishac Nazy
Journal:  Int J Lab Hematol       Date:  2019-05-03       Impact factor: 2.877

2.  The Effect of Prophylactic Doses of Reviparin on the Postoperative Value of Platelets.

Authors:  Ismet Suljevic; Suad Basic; Ismana Surkovic; Maida Turan; Ehlimana Musija
Journal:  Med Arch       Date:  2019-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.